

Clinical Policy: Droxidopa (Northera)

Reference Number: CP.PMN.17

Effective Date: 08.01.16

Last Review Date: 11.17

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Droxidopa (Northera[®]) is a synthetic amino acid precursor of norepinephrine.

FDA approved indication

Northera is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Northera should be assessed periodically

Policy/Criteria

Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Centene Corporation[®] that Northera is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Neurogenic Orthostatic Hypotension** (must meet all):

1. Diagnosis of symptomatic nOH caused by one of the following (a, b, or c):
 - a. Primary autonomic failure (PD, multiple system atrophy, or pure autonomic failure);
 - b. Dopamine beta-hydroxylase deficiency;
 - c. Non-diabetic autonomic neuropathy;
2. Age \geq 18 years;
3. Failure of midodrine or fludrocortisone at up to maximally indicated doses, unless both are contraindicated or clinically significant adverse are experienced;
4. Dose does not exceed 1800 mg per day (6 capsules/day).

Approval duration: 14 days

B. Other diagnoses/indications

1. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

CLINICAL POLICY

Droxidopa

II. Continued Therapy

A. Neurogenic Orthostatic Hypotension (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. One year (365 days) has elapsed since previous treatment with Northera;
3. If request is for a dose increase, new dose does not exceed 1800 mg per day (6 capsules/day).

Approval duration: 14 days

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 12 months (whichever is less); or

2. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

nOH: Neurogenic orthostatic hypotension

Appendix B: Black Box Warning – Supine Hypertension

Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue Northera.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
nOH	100 mg PO three times during the day, titrate by 100 mg three times daily	600 mg three times daily

VI. Product Availability

Capsules: 100 mg, 200 mg, and 300 mg

VII. Workflow Document



Northera WF.docx

CLINICAL POLICY
Droxidopa

VIII. References

1. Northera Prescribing Information. Deerfield, IL: Lundbeck; February 2017. Available at: http://www.lundbeck.com/upload/us/files/pdf/Products/Northera_PI_US_EN.pdf. Accessed July 2017.
2. Vijayan J, Sharma VK. Neurogenic orthostatic hypotension - management update and role of droxidopa. *Ther Clin Risk Manag.* 2015 Jun 8;11:915-23.
3. Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a difficult problem. *Expert Rev Cardiovasc Ther.* 2015 Nov;13(11):1263-76. doi: 10.1586/14779072.2015.1095090. Epub 2015 Oct 1.
4. Shibao C, Lipsitz LA, Biaggioni I et al. Evaluation and treatment of orthostatic hypotension. *J Am Soc Hypertens.* 2013 Jul-Aug;7(4):317-24. doi: 10.1016/j.jash.2013.04.006. Epub 2013 May 27.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created.	04.16	08.16
Converted to integrated template; Removed requirement of a medication being prescribed by or in consultation with a specialist; Added required conditions of autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy; Added maximum dose of 1800mg/day.	10.16	11.16
-Added age and Appendix B, black box warning. Updated references.	07.01.17	11.17

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

CLINICAL POLICY**Droxidopa**

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.